Randomized, open-label, multicentre pharmacokinetic studies of two dose levels of pantoprazole granules in infants and children aged 1 month through <6 years with gastro-oesophageal reflux disease

Clinical Pharmacokinetics

Volumn 50, Issue 8, 2011, Pages 541-550

  Tammara, Brinda K ^a   Sullivan, Janice E ^b   Adcock, Kim G ^c   Kierkus, Jaroslaw ^d   Giblin, John ^e   Rath, Natalie ^a   Meng, Xu ^a   Maguire, Mary K ^a   Comer, Gail M ^a   Ward, Robert M ^f  

^a PFIZER INC   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^e Clinical Study Centers LLC   (United States)

^f UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Children; Gastro oesophageal reflux; Infants; Pantoprazole; Proton pump inhibitors

Indexed keywords

PANTOPRAZOLE;

ABDOMINAL PAIN; ACCIDENTAL INJURY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHILD; CLINICAL ARTICLE; CONTACT DERMATITIS; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG CLEARANCE; DRUG FEVER; DRUG GRANULE; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FEMALE; FOOD AND DRUG ADMINISTRATION; GASTROENTERITIS; GASTROESOPHAGEAL REFLUX; HUMAN; INFANT; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PATIENT MONITORING; PHARMACOGENOMICS; PLASMA CONCENTRATION-TIME CURVE; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; ROTAVIRUS INFECTION; SIDE EFFECT; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; TOOTH DISEASE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADMINISTRATION, ORAL; AGE FACTORS; AREA UNDER CURVE; CHILD, PRESCHOOL; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; INFANT; MALE; PROTON PUMP INHIBITORS; SUSPENSIONS;

EID: 79960201144     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11591900-000000000-00000     Document Type: Article

References (36)

1. Sherman PM, Hassall E, Fagundes-Neto U, et al. A global, evidence-based consensus on the definition of gastroesophageal reflux disease in the pediatric population. Am J Gastroenterol 2009; 104: 1278-95.
2. Vandenplas Y, Rudolph CD, Di Lorenzo C, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society of Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society of Pediatric Gastroenterology, Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr 2009 Sep 9; 49: 498-547.
3. Poets C. Gastroesophageal reflux: a critical review of its role in preterm infants. Pediatrics 2004; 113 (2): e128-32.
4. Rudolph CD. Are proton pump inhibitors indicated for the treatment of gastroesophageal reflux in infants and children? J Pediatr Gastroenterol Nutr 2003; 37: S60-4.
5. Cezard J. Managing gastro-oesophageal reflux disease in children. Digestion 2004; 69 (Suppl. 1): S3-8.
6. Orenstein SR, Hassall E, Furmaga-Jablonska W, et al. Multicenter, double- blind, randomized, placebo-controlled trial assessing the efficacy and safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154 (4): 514-20.
7. Winter H, Kum-Nji P, Mahomedy S, et al. Efficacy and safety of pantoprazole delayed-release granules for oral suspension in a placebo-controlled treatment-withdrawal study in infants 1 through 11 months with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2010 June; 50 (6): 609-18.
8. Winter H, Gunasekaran T, Tolia V, et al. Esomeprazole for the treatment of gastroesophageal reflux disease (GERD) in infants [abstract no. T1123]. Gastroenterology 2009; 136 (5 Suppl. 1): A-504.
9. Baker R, Tsou VM, Tung J, et al. Clinical results from a randomized, double- blind, dose-ranging study of pantoprazole in children aged 1 through 5 years with symptomatic histologic or erosive esophagitis. Clin Pediatr (Phila) 2010 Sep; 49 (9): 852-65.
10. Tolia V, Bishop P, Tsou V, et al. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5-11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006; 42 (4): 384-91. (Pubitemid 43841020)
11. Tsou VM, Baker R, Book L, et al. Multicenter, randomized, double-blind study comparing 20 and 40 mg of pantoprazole for symptom relief in adolescents (12 to 16 years of age) with gastroesophageal reflux disease (GERD). Clin Pediatr (Phila) 2006; 45 (8): 741-9. (Pubitemid 44359194)
12. Gilger MA, Tolia V, Vandenplas Y, et al. Safety and tolerability of esome- prazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2008 May; 46 (5): 524-33.
13. Gold BD, Gunasekaran T, Tolia V, et al. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007 Nov; 45 (5): 520-9. (Pubitemid 350307136)
14. Richter JE, Fraga P, Mack M, et al. Prevention of erosive oesophagitis relapse with pantoprazole. Aliment Pharmacol Ther 2004; 20 (5): 567-75. (Pubitemid 39243902)
15. Dettmer A, Vogt R, Sielaff F, et al. Pantoprazole 20 mg is effective for relief of symptoms and healing of lesions in mild reflux oesophagitis. Aliment Pharmacol Ther 1998; 12 (9): 865-72. (Pubitemid 28428951)
16. Armstrong D, Pare P, Pericak D, et al. Symptom relief in gastroesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive esophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96 (10): 2849-57. (Pubitemid 32959523)
17. Hogan D, Pratha V, Riff D, et al. Oral pantoprazole in the form of granules or tablets are pharmacodynamically equivalent in suppressing acid output in patients with gastro-oesophageal reflux disease and a history of erosive oesophagitis. Aliment Pharmacol Ther 2007; 26 (2): 249-56. (Pubitemid 46985503)
18. Protonix® (pantoprazole sodium) delayed-release tablets and Protonix® (pantoprazole sodium) for delayed-release oral suspension: US package insert. Collegeville (PA): Wyeth, 2009.
19. Tammara B, Weisel K, Katz A, et al. Bioequivalence study of pantoprazole granules administered to healthy subjects: oral administration with applesauce and apple juice and by nasogastric tube. Am J Health Syst Pharm 2009; 66: 1923-8.
20. Tammara B, Orczyk G, Nightingale C, et al. Bioavailability of the new pan- toprazole spheroid formulation to the currently marketed tablet formulation in healthy adult subjects [abstract no. 275]. AAPS J 2004; 6 (Suppl. 1) [online]. Available from URL: http://www.aapsj.org/abstracts/AM-2004/AAPS2004- 000275.PDF [Accessed 2011 Apr 27].
21. Tanaka M, Ohkubo T, Otani K, et al. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype. Clin Pharmacol Ther 1997; 62 (6): 619-28. (Pubitemid 28068065)
22. Furuta T, Shirai N, Sugimoto M, et al. Pharmacogenomics of proton pump inhibitors. Pharmacogenomics 2004; 5 (2): 181-202. (Pubitemid 38351277)
23. Leeder J. Pharmacogenetics and pharmacogenomics. Pediatr Clin North Am 2001; 48: 765-81. (Pubitemid 32521715)
24. Huber R, Hartmann M, Bliesath H, et al. Pharmacokinetics of pantoprazole in man. Int J Clin Pharmacol Ther 1996; 34 (5): 185-94. (Pubitemid 26148501)
25. Comer G, Kierkus J, Sullivan J, et al. Pharmacodynamics (PD) and safety of pantoprazole delayed-release granules in infants aged 1 through 11 months with a clinical diagnosis of gastroesophageal reflux disease (GERD). Gastroenterology 2009; 136 (5 Suppl. 1): A-443-4.
26. Tammara B,AdcockK, Kearns G,et al. Pharmacokinetics of two dose levels of pantoprazole sodium granules and tablets in children aged 1 through 11 years with endoscopically proven GERD [abstract no. 1348]. Am J Gastroenterol 2008; 103 (Suppl. 1): S528-9.
27. Comer G, Tammara B, Adcock K, et al. Pharmacokinetics of intravenous pantoprazole in children ages 1 to 16 years [abstract no. 1023]. Am J Gas-troenterol 2005; 100 (Suppl. 9s): s373.
28. Kearns GL, Blumer J, Schexnayder S, et al. Single-dose pharmacokinetics of oral and intravenous pantoprazole in children and adolescents. J Clin Pharmacol 2008; 48 (11): 1356-65.
29. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008; 48: 303-32. (Pubitemid 351738156)
30. Hines RN, McCarver DG. The ontogeny of human drug-metabolizing en- zymes: phase I oxidative enzymes. J Pharmacol Exp Ther 2002; 300: 355-60. (Pubitemid 34106223)
31. Tammara B, Ward R, Kearns G, et al. Pharmacokinetics of single and multiple doses of pantoprazole in adolescents with GERD [abstract no. 1347]. Am J Gastroenterol 2008; 103 (Suppl. 1): S528
32. Holford N. Dosing in children. Clin Pharmacol Ther 2010; 87 (3): 367-70
33. Horn JR, Howden CW. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations. Aliment Pharmacol Ther 2005; 22 (Suppl. 3): 20-4. (Pubitemid 41783983)
34. Andersson T, Hassall E, Lundborg P, et al. Pharmacokinetics of orally ad- ministered omeprazole in children. Am J Gastroenterol 2000; 95 (11): 3101-6.
35. Tran A, Rey E, Pons G, et al. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children. Clin Pharmacol Ther 2002 May; 71 (5): 359-67. (Pubitemid 34518146)
36. Koukouritaki S, Manro J, Marsh S, et al. Developmental expression of human hepatic CYP2C9 and CYP2C19. J Pharmacol Exp Ther 2004; 308 (3): 965-74 (Pubitemid 38263972)